期刊文献+

安博维对兔心肌梗死后心功能及基质金属蛋白酶-3表达的影响 被引量:1

Effect of Aprovel Therapy to Heart Function and MMP-3 Expression after Acute Myocardial Infarction in Rabbits
下载PDF
导出
摘要 目的:研究兔心肌梗死后基质金属蛋白酶3(MMP-3)在心室重构和心衰形成中的变化及安博维对其的影响。方法:采用兔冠状动脉前降支结扎法建立兔心肌梗死模型。将28只新西兰兔随机分为伪手术组,心肌梗死组,药物干预组。手术前及手术后10周心超检测室间隔厚度(LVSd)、左室后壁厚度(LVPW d),左室射血分数(EF)。用W estern B lot法测定10周后心肌组织的基质金属蛋白酶3的含量。结果:手术后10周时,药物干预组LVSd,LVPW d明显低于心肌梗死组(P<0.05);左室射血分数明显高于心肌梗死组(P<0.05),但低于伪手术组(P<0.05)。心肌梗死后MMP-3表达升高,相对含量与EF呈负相关。结论:MMP-3参与了左室重构和心肌梗死后心衰的形成。安博维通过抑制MMP-3的表达,明显减轻心肌梗死后心肌肥厚,改善左室功能。 Objective: To investigate the change of matrix metalloproteinases during the ventricular remodeling and heart failure induced after acute myocardial infarction in rabbits and the effect of Aprovel.Methods: Rabbits myocardial infarction model was established by permanent ligation of left anterior descending coronary artery. Twenty-eight New Zealand rabbits were randomized divided into 3 groups:sham group, infarcted group and drug treatment group. Pre-operation and 10 weeks after operation, the interventricular septum thickenss (IVSd), left ventricular posterior wall thickness (LVPWd), left ventricular ejection fraction(EF) were measured by echocardiography. Expression of MMP-3 protein in myocardium tissues was quantified by Western Blotting. Results: At lOth week, both IVSd and LVPWd had a significant decrease in drug treatment group compared with those of infarcted group ( P 〈 0. 05 ). EF was obviously increased ( P 〈 0. 05) ,but still lower than sham group(P 〈0. 05). Expression of MMP-3 protein increased after myocardial infarction. The level of MMP-3 was correlated negatively with the EF. Conclusion: The alteration of MMP-3 contribute to the ventricular remodeling and heart failure induced after acute myocardial infarction.Aprovel can reduce myocardial hypertrophy,improve heart function by reducing the activity of MMP-3.
出处 《江苏大学学报(医学版)》 CAS 2006年第2期116-119,共4页 Journal of Jiangsu University:Medicine Edition
关键词 安博维 心肌梗死 心功能 基质金属蛋白酶 Aprovel Myocardial infarction Heart function Rabbit Matrix metalloproteinases
  • 相关文献

参考文献16

  • 1Gheorghiade M,Bonow RO.Chronic heart failure in the United States:a manifestation of coronary artery disease[J].Circulation,1998,97:282-289.
  • 2Dzau V.Cardiac renin-angiotensin system:molecular and functional aspects[J].Am J Med,1998,84 (Suppl 3A):22 -27.
  • 3Goodfriend TL,Elliotc ME,Cao K J,et al.Angiotensin receptors and their antagonist[J].N Engl J Med,1996,334:1649-1661.
  • 4Lindsey ML,Mann DL,Entman ML,et al.Extracellular matrix remodeling following myocardial injury[J].Ann Med,2003,35(5):316-326.
  • 5Pye MP,Black M9 Cobbe SM.Comparison of in vivo and in vitro haemodynamic function in experimental heart failure:Use of echocardiography[J].Cardiovas Res,1996,31 (1):873 -881.
  • 6Voors AA,Pinto YM,Buikema H,et al.Dual pathway for angiotensin Ⅱ formation in human internal mammary arteries[J].Br J Pharmacol,1998,125:1028-1032.
  • 7Walsh JT,Batin PD,Hawkins M,et al.Ventricular dilatation in the absence of ACE inhibiotrs:influence of haemodynamic and neurohormonal variables following myocardial infarction[J].Heart,1999,81 (1):33-39.
  • 8Pfeffer MA,Mcmurray J,Leizorovicz A,et al.Valsartan in acute myocardial infarction trial (VALIANT):Rationale and design[J].Am Heart J,2000,140:727-734.
  • 9De Carvalho Frimm C,Sun Y,Weber KT,et al.Angiotensin Ⅱ receptor blockade and myocardial fibrosis of the infarcted rat heart[J].J Lab Clin Med,1997,129(4):439-446.
  • 10JUH,Zhao S,Jassal DS,et al.Effect of AT1 receptor blockade on cardiac collagen remodeling.after myocardial infarction[J].Cardiovase Res,1997,35:223-237.

同被引文献29

  • 1王晓健,惠汝太.一个新的保护心脏TGF-β超家族成员——GDF15[J].中国分子心脏病学杂志,2006,6(4):242-245. 被引量:5
  • 2董兆强,鹿庆华,郝林,王欣,蒋卫东,齐昕.充血性心力衰竭患者血清基质金属蛋白酶-2浓度的变化及其临床意义[J].中国老年学杂志,2007,27(6):548-550. 被引量:11
  • 3[1]Thom T,Haase N,Rosamond W,et al.Heart disease and stroke statistics-2006 update:a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee[J].Circulation,2006,113 (6):e85-151.
  • 4[3]Bax JJ,Abraham T,Barold SS,et al.Cardiac resynchronization therapy part 1-Issues before device implantation[J].J Am Coll Cardiol,2005,46 (12):2153-2167.
  • 5[4]Zhang Q,Fung JW,Auricchio A,et al.Differential change in left ventricular mass and regional wall thickness after cardiac resynchronization therapy for heart failure[J].Eur Heart J,2006,27 (12):1423-1430.
  • 6[5]N.Van De Veire,G.B.Bleeker,J.De Sutter,et al.Tissue synchronisation imaging accurately measures left ventricular dyssynchrony and predicts response to cardiac resynchronisation therapy[J].Heart,2007,93 (9):1034-1039.
  • 7[6]Murdoch DR,McDonough TA,Byrne J,et al.Titration of vasodilator therapy in chronic heart failure according to plasma brain natriuretic peptide concentration:randomized comparison of the hemodynamic and neuroendocrine effects of tailored versus empirical therapy[J].Am Heart J,1999,138 (6 Pt 1):1126-1132.
  • 8[7]Latini R,Masson S,Anand I,et al.Effects of valsartan on circulating brain natriuretic peptide and norepinephrine in symptomatic chronic heart failure:the Valsartan Heart Failure Trial (Val-HeFT)[J].Circulation.2002,106 (19):2454-2458.
  • 9[8]Maisel AS.The diagnosis of acute congestive heart failure:role of BNP measurements[J].Heart Fail Rev,2003,8 (4):327-334.
  • 10[9]Januzzi JL,van Kimmenade R,Lainchbury J,et al.NT-proBNP testing for diagnosis and short-term prognosis in acute destabilized heart failure:an international pooled analysis of 1256 patients:the International Collaborative of NT-proBNP Study[J].Eur Heart J,2006,27 (3):330-337.

引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部